title: Comparison of the effects of a new conjugated oral estrogen, estradiol-3beta-glucoside, with oral micronized 17beta-estradiol in postmenopausal women.
abstract: The objective of this article is to evaluate the pharmacokinetics of serum estrone and estradiol levels in women who were taking either 17beta-estradiol-3beta-glucoside (E(2)-3beta-glucoside) or 17beta-estradiol (E(2)) daily and to examine the effects of E(2)-3beta-glucoside and E(2) on postmenopausal symptoms, gonadotropins, hepatic metabolism, and coagulation factors. Healthy postmenopausal women on estrogen who had undergone a hysterectomy were recruited. Subjects were randomly assigned to receive equivalent doses of either E(2)-3beta-glucoside or micronized E(2) for 28 days. Pharmacokinetic studies of estrone and estradiol were performed on days 1, 2, 28, and 29. Gonadotropin levels and Kupperman Index (KI) scores were determined at baseline and on treatment day 28. Mean serum estradiol and estrone concentrations in those taking E(2)-3beta-glucoside were comparable with those taking E(2). Mean baseline follicle stimulating hormone (FSH) levels were 84 +/- 27 mIU/mL and 71 +/- 24 mIU/mL in the E(2)-3beta-glucoside and E(2) groups, respectively, with significant decreases (P < 0.01) of 54 +/- 21 mIU/mL and 38 +/-18 mIU/mL, respectively, by treatment day 28. Baseline KI scores in the E(2)-3beta-glucoside group were 10 +/- 6 compared with 5 +/- 4 on treatment day 28, which is equivalent to a 50% reduction in menopausal symptoms (P = 0.003). The change in KI scores in the E(2) group was not statistically significant. Total serum estradiol and estrone levels in women taking E(2)-3beta-glucoside are comparable with those in women taking E(2). E(2)-3beta-glucoside reduces serum gonadotropin levels to the premenopausal range and is effective at reducing postmenopausal symptoms. E(2)-3beta-glucoside is a novel synthetic estrogen that is well tolerated and has promise as a hormone replacement therapy.
authors.affiliation: Division of Endocrinology, Department of Medicine, Tufts University School of Medicine, Caritas St. Elizabeth's Medical Center, Boston, MA, USA.
authors.forename: Ann T
authors.initials: AT
authors.lastname: Sweeney
authors.forename: Vin
authors.initials: V
authors.lastname: Tangpricha
authors.forename: Janice
authors.initials: J
authors.lastname: Weinberg
authors.forename: Alan O
authors.initials: AO
authors.lastname: Malabanan
authors.forename: Farhad N
authors.initials: FN
authors.lastname: Chimeh
authors.forename: Michael F
authors.initials: MF
authors.lastname: Holick
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D004339:Drug Compounding; D004958:Estradiol / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000493:pharmacokinetics*; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004970:Estrone / Q000097:blood*; D005260:Female; D006062:Gonadotropins / Q000097:blood*; D006801:Humans; D008875:Middle Aged; D010316:Particle Size; D010865:Pilot Projects; D017698:Postmenopause / Q000378:metabolism*; D012720:Severity of Illness Index
chemical_list: D045166:Estradiol Congeners; D006062:Gonadotropins; C014529:estradiol-3-glucoside; D004970:Estrone; D004958:Estradiol